NCT01505504

Mirtazapine in Alzheimer-associated Weight Loss

Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 22 (actual)
• Sponsor: Brugmann University Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect. The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).

Conditions

• Alzheimer's Disease
• Weight Loss
• Mixed Dementia
• Dementia

Interventions

Type	Name	Description
DRUG	mirtazapine	30 mg at bedtime

Timeline

• Start date: 2004-01-01
• Primary completion: 2011-11-01
• Completion: 2011-12-01
• First posted: 2012-01-06
• Last updated: 2012-01-06

Locations

1 site across 1 country: Belgium